Tag: sirolimus

Can sirolimus-coated balloons overcome current treatment challenges for chronic limb-threatening ischaemia...

 Eric Secemsky (Boston, USA) and Edward Choke (Singapore) discuss the role of sirolimus-coated balloons in the treatment of peripheral arterial disease (PAD), particularly below...
MedAlliance SELUTION SLR

Twelve-month results from SELUTION SFA trial presented at JET

Twelve-month results from the SELUTION SFA trial have been presented for the first time at the Japan Endovascular Treatment (JET) Conference (26–28 May, Tokyo,...

First US patient enrolled in MedAlliance sirolimus DCB study

The first US patient has been enrolled in the SELUTION4SFA sirolimus drug-eluting balloon (DEB) study by Arthur Lee (Cardiac & Vascular Institute, Gainesville, USA)....
Surmodics

Surmodics provides regulatory update related to its FDA premarket approval application...

Surmodics recently announced it has received a letter from the US Food and Drug Administration (FDA) related to its premarket approval (PMA) application for...
SIRONA

SIRONA trial enrolment completed

Concept Medical has announced the successful completion of enrolment for the SIRONA randomised controlled trial (RCT) investigating the use of its Magic Touch PTA...
SIRONA

Concept Medical’s SIRONA trial completes enrolment

Concept Medical has announced the completion of patient enrolment in the SIRONA trial. According to the company, this is the world's first and the...
Cordis

Cordis announces acquisition of MedAlliance

Cordis today announced its acquisition, subject to customary closing conditions including regulatory approvals, of MedAlliance. A press release notes that the agreement includes an...
Surmodics

Six-month data from the Surmodics SWING BTK first-in-human trial presented at...

Six-month data from the Surmodics SWING first-in-human (FIH) study of the company’s Sundance sirolimus drug-coated balloon (DCB) were shared at the 2022 Amputation Prevention...
Motiv

Preliminary MOTIV BTK outcomes positive for bioresorbable scaffold use in below-the-knee...

Thomas Rand (Klinik Florisdorf, Vienna, Austria) recently presented on the preliminary results to 12 months of the Motiv bioresorbable scaffold (Reva Medical) postmarket trial...

Sirolimus-coated balloon a “clear alternative” to paclitaxel-coated balloons

 Ulf Teichgräber (Jena, Germany) and Edward Choke (Singapore) discuss—at the 2022 Charing Cross (CX) International Symposium (26–28 April, London, UK)—some of the key benefits...
Selution

First US patient enrolled in Selution SLR IDE peripheral study

The first US patient has been enrolled in the US Food and Drug Administration (FDA) SELUTION4BTK (below-the-knee) clinical trial evaluating Selution SLR, MedAlliance's novel...
Selution

Selution SLR receives second FDA IDE approval

Selution SLR, MedAlliance's sirolimus-eluting balloon, has received conditional US Food and Drug Administration (FDA) investigational device exemption (IDE) approval to initiate its pivotal clinical...
top 10

Vascular News’ top 10 most popular stories of May 2022

Two-year data on the use of intravascular lithotripsy (IVL) in calcified peripheral disease treatment, an advertorial sponsored by Bentley exploring the role of bridging...

SIRONA head-to-head randomised trial achieves 50% enrolment

Concept Medical recently announced that the SIRONA randomised controlled trial (RCT)—a head-to-head comparison of sirolimus versus paclitaxel drug-eluting balloon angioplasty in the femoropopliteal artery—has...
MedAlliance SELUTION SLR

MedAlliance acquires Japanese partner MDK Medical

MedAlliance has acquired its partner MDK Medical, a Japanese vascular specialist company. MDK Medical has previously worked closely with MedAlliance in developing Japanese clinical...
SIRONA

IMPRESSION trial assessing MagicTouch AVF passes 50% enrolment

Concept Medical has shared the latest update from its IMPRESSION (Sirolimus-coated balloon angioplasty versus plain balloon angioplasty in the treatment of dialysis access dysfunction)...
MedAlliance SELUTION SLR

Eighteen-month PRESTIGE BTK data presented at VIVA 2021

Eighteen-month results from the PRESTIGE below-the-knee (BTK) study were presented as a late-breaking clinical trial at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA). The...
MedAlliance SELUTION SLR

Japanese Selution SLR study completes enrolment

MedAlliance, with its Japanese partner MDK Medical, has completed enrolment in the clinical study of its novel sirolimus drug-eluting balloon (DEB), Selution SLR, for...
R3 Vascular

R3 Vascular reports the initiation of its first-in-human clinical study

R3 Vascular has reported the successful initiation of its first-in-human clinical study evaluating the technical and clinical performance of the R3 Vascular Magnitude bioresorbable...

PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrolment

  MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of...
MedAlliance SELUTION SLR

PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrolment

MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of...
magictouch scb

Concept Medical provides update on IMPRESSION trial to evaluate MagicTouch AVF

Concept Medical has provided an update on the progress of the IMPRESSION (Sirolimus-coated balloon angioplasty versus plain balloon angioplasty in the treatment of dialysis...
trerotola misra tan av access dcbs drug coated balloons

More mixed results for DCBs in AV access maintenance as evidence...

Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
MagicTouch

Concept Medical releases status updates on SIRONA RCT

Concept Medical has released a series of status updates on their head-to-head SIRONA (Sirolimus versus paclitaxel drug-eluting balloon angioplasty in femoropopliteal diseases) randomised controlled...
MedAlliance SELUTION SLR

MedAlliance raises over US$50 million to roll out Selution SLR and...

MedAlliance recently announced that it has raised over US$50 million in equity funding. The new investor is Trustar Capital (formerly known as CITIC Capital...

Efemoral Medical announces successful first-in-human use of the Efemoral vascular scaffold...

Efemoral Medical has announced the first-in-human (FIH) use of the company's Efemoral vascular scaffold system (EVSS) with FlexStepv technology in the EFEMORAL I FIH...
MedAlliance SELUTION SLR

First two patients enrolled in PRISTINE study with Selution SLR

MedAlliance has announced enrolment of the first two patients in the PRISTINE registry with Selution sustained limus release (SLR) 018 drug-eluting balloon (DEB) for...
MedAlliance SELUTION SLR

First sirolimus DEB patient enrolled in Japanese Selution SLR study

MedAlliance’s partner in Japan, MDK Medical, has enrolled the first patient in the clinical study of its novel sirolimus (SLR) drug-eluting balloon (DEB), Selution...
MedAlliance SELUTION SLR

First patient enrolled globally in SELUTION SLR study for AV fistulae

MedAlliance has announced enrolment of the first patient in the SAVE (Use of the Selution sirolimus-eluting balloon for dysfunctional AV access treatment indications) study...
Disrupt PAD III

Sirolimus on the rise but paclitaxel “will probably come back again”

At this year’s Leipzig Interventional Course (LINC 2020; 28–31 January, Leipzig, Germany), William Gray (Main Line Health, Philadelphia, USA) considered the future of drug-coated...

Alvimedica introduces SFA sirolimus-eluting stent

At the Leipzig Interventional Course 2020 (LINC; 28–31 January, Leipzig, Germany), Alvimedica held a Lunch Symopsium in which they introduced a new in-stent treatment...
MedAlliance SELUTION SLR

MedAlliance receives CE mark approval for SELUTION SLR sirolimus drug-eluting balloon...

MedAlliance has announced the award of its first CE mark approval: for SELUTION SLR, a novel sirolimus drug-eluting balloon (DEB), for the treatment of...
MedAlliance SELUTION SLR

MedAlliance receives third FDA breakthrough device designation for its sirolimus DEB...

MedAlliance, the first drug-eluting balloon (DEB) company in the world to receive US Food and Drug Administration (FDA) breakthrough device designation status for a...

Patient enrolment completed in MedAlliance PRESTIGE BTK clinical trial

MedAlliance has announced completion of patient enrolment in the PRESTIGE below-the-knee (BTK) clinical trial. The objective of this clinical investigation is to evaluate the...

VIVA 2019: SELUTION sirolimus DCB safe and effective through two years

The SELUTION SFA trial met its primary endpoint and demonstrated an late lumen loss of 0.19mm. Furthermore, excellent freedom from clinically driven TLR was...

Sundance sirolimus-coated balloon catheter granted FDA breakthrough device designation

Surmodics has announced that the US Food and Drug Administration (FDA) has designated its Sundance sirolimus-coated balloon catheter as a breakthrough device under the...
MagicTouch

Concept Medical granted CE certification for sirolimus-coated MagicTouch group of products

Concept Medical received CE certification for their MagicTouch group of products on 16 October 2019. The CE certified products/brands are as listed below: MagicTouch—PTA (sirolimus-coated...

Vascular Therapies announce positive preliminary clinical results from its AV fistula...

Vascular Therapies is developing Sirogen, a proprietary sirolimus formulation for intraoperative local, perivascular drug delivery focused on improving vascular access outcomes in patients with...

MagicTouch AVF sirolimus-coated balloon granted breakthrough device designation for use in...

Concept Medical has been granted breakthrough device designation from the US Food and Drug Administration (FDA) for MagicTouch AVF, its sirolimus drug-coated balloon (DCB)...
Motiv

MagicTouch PTA sirolimus coated balloon granted breakthrough device designation by FDA

Concept Medical has been granted breakthrough device designation from the US Food and Drug Administration (FDA) for its MagicTouch percutaneous transluminal angioplasty (PTA) sirolimus...

Positive AV fistula outcomes following intraoperative pharmacological intervention using a perivascularly...

Intraoperative perianastomotic delivery of sirolimus is feasible, according to Sriram Iyer (Lenox Hill Hospital, New York, USA). Based on preliminary data from 56 arteriovenous...

Virtue sirolimus-eluting balloon set for commercial release as Terumo and Orchestra...

Orchestra BioMed and Terumo have formed a global strategic partnership for the development and commercialisation of Virtue sirolimus-eluting balloon (SEB) in the percutaneous coronary...
ILLUMENATE

Late-breaking ILLUMENATE data demonstrate three-year safety and efficacy for Stellarex DCB

Three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European randomised controlled trial (EU RCT) have been presented in a late-breaking trial session...

Sirolimus has “a much wider” safety window and shows fewer local...

 "Paclitaxel kills the cells in the artery wall; sirolimus simply stuns them," says Peter Gaines (Sheffield, UK). Gaines commented at the 2019 Vascular Leaders...

US$60 million raised to fund sirolimus-coated balloon investigational trial

Concept Medical Inc. has approached the FDA for an investigational device exemption (IDE) for their sirolimus-coated balloon (DCB). To support this process, they have...

First-in-man study of Med Alliance’s Selution sirolimus-coated balloon completes enrolment

Med Alliance has announced the on-schedule completion of patient enrolment in the first-in-man (FIM) study of Selution, the company’s sirolimus-coated balloon. Fifty patients have...

Initial patients enrolled in first-in-man study of Selution sirolimus-coated balloon

Med Alliance has announced first patient enrolment in the first-in-man study of the Selution novel sirolimus-coated balloon. Patients were enrolled at the Universitaets-Herzzentrum, Bad...